PRODUCT INFORMATION



PPARα Ligand-binding Domain (human, recombinant)

Item No. 10009088

Overview and Properties

Synonyms: Peroxisome Proliferator-activated Receptor α Ligand Binding Domain, PPARα LBD Source: Recombinant human His-tagged PPARα ligand-binding domain expressed in E. coli

Amino acids: 170-430 **Uniprot No.:** Q07869

Molecular Weight: ~34 kDa/subunit Storage: -80°C (as supplied)

Stability: ≥1 year

Purity: batch specific (≥55% estimated by SDS-PAGE)

Supplied in: 50 mM sodium phosphate, pH 7.2, containing 20% glycerol and 100 mM sodium

chloride

Protein

batch specific mg/ml Concentration:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Image



Lane 1: MW Markers

Lane 2: PPARa LBD (human recombinant) (4 µg) Lane 3: PPARα LBD (human recombinant) (2 μg) Lane 4: PPARa LBD (human recombinant) (1 µg)

Representative gel image shown; actual purity may vary between each batch.

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/16/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Peroxisome proliferator-activated receptor α (PPAR α) is a member of the nuclear receptor family of ligand-activated transcription factors that regulates a variety of metabolic functions and inflammation. 1 It contains an N-terminal domain that is subject to phosphorylation, a DNA-binding domain, and a C-terminal ligand-binding domain.² PPARα is highly expressed in tissues with high fatty acid oxidation rates, including the liver, heart, skeletal muscle, brown adipose tissue, and kidney, as well as in macrophages and T cells.^{2,3} It is activated by a variety of endogenous ligands such as fatty acids, eicosanoids, and endocannabinoids, as well as synthetic agents, including fenofibrate (Item No. 10005368) and gemfibrozil (Item No. 14835).4 Upon activation, PPARα heterodimerizes with the retinoid X receptor (RXR) and binds to PPAR response elements in PPARα target genes, recruiting RNA polymerase II and initiating gene transcription. PPARα transcriptionally regulates a variety of genes involved in several cellular processes, including lipid and hormone transport, peroxisomal and mitochondrial β -oxidation, amino acid metabolism, and inflammation.^{1,2} Genome-wide deletion of Ppara protects mice from high-fat diet-induced hyperinsulinemia and insulin resistance. PPARA SNPs have been found in individuals with a variety of cardiovascular conditions, including hypertension, atherosclerosis, coronary artery disease, left ventricular hypertrophy, or myocardial infarction. ¹ Formulations containing PPARα agonists have been used in the treatment of hyperlipidemia. Cayman's PPARα Ligand-binding Domain protein can be used for Western blot (WB) applications.

References

- 1. Li, S., Yang, B., Du, Y., et al. Targeting PPARα for the treatment and understanding of cardiovascular diseases. *Cell Physiol. Biochem.* **51(6)**, 2760-2775 (2018).
- 2. Pawlak, M., Lefebvre, P., and Staels, B. Molecular mechanism of PPARa action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. *J. Hepatol.* **62**, 720-733 (2015).
- 3. Rakhshandehroo, M., Knoch, B., Müller, M., et al. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. (2010).
- 4. Ruscica, M., Busnelli, M., Runfola, E., et al. Impact of PPAR-Alpha polymorphisms-the case of metabolic disorders and atherosclerosis. *Int. J. Mol. Sci.* **20(18)**, 4378 (2019).
- 5. Guerre-Millo, M., Rouault, C., Poulain, P., et al. PPAR-α-null mice are protected from high-fat diet-induced insulin resistance. *Diabetes* **50(12)**, 2809-2814 (2001).

ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897